Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Maria Marsella & Paolo Ricchi. (2019) Thalassemia and hepatocellular carcinoma: links and risks. Journal of Blood Medicine 10, pages 323-334.
Read now
Read now
Abhishek Yadav & Swaran Jeet Singh Flora. (2016) Nano drug delivery systems: a new paradigm for treating metal toxicity. Expert Opinion on Drug Delivery 13:6, pages 831-841.
Read now
Read now
Elham Ghahramanlu, Abdollah Banihashem, Naghme-Zahra Mirhossini, Golkoo Hosseini, Hesam Mostafavi-Toroghi, Shima Tavallaie, Mojtaba Meshkat, Majid Ghayour-Mobarhan & Gordon Ferns. (2014) Effect of zinc supplementation on serum antibody titers to heat shock protein 27 in patients with thalassemia major. Hematology 19:2, pages 113-119.
Read now
Read now
Articles from other publishers (17)
Zahra Tariq, Muhammad Imran Qadeer, Iram Anjum, Christophe Hano & Sumaira Anjum. (2023) Thalassemia and Nanotheragnostics: Advanced Approaches for Diagnosis and Treatment. Biosensors 13:4, pages 450.
Crossref
Crossref
Guy Rostoker, Patricia Senet, Fanny Lepeytre, Mireille Griuncelli, Christelle Loridon, Clémentine Rabaté & Yves Cohen. (2021) Analysis of liver iron concentration in an elderly female undergoing hemodialysis with calcific uremic arteriolopathy does not support the role of iron overload in calciphylaxis: lesson for the clinical nephrologist. Journal of Nephrology 34:5, pages 1547-1551.
Crossref
Crossref
Tzu-Yao Chuang, Ju-Pi Li, Te-Fu Weng, Kang-Hsi Wu & Yu-Hua Chao. (2020) Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications. Annals of Hematology 99:10, pages 2289-2294.
Crossref
Crossref
Guy Rostoker & Nosratola D. Vaziri. (2019) Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations. Heliyon 5:7, pages e02045.
Crossref
Crossref
Nancy F. Olivieri, Amir Sabouhanian & Brenda L. Gallie. (2019) Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. PLOS ONE 14:2, pages e0211942.
Crossref
Crossref
Sylvia T. Singer. 2017. Pediatric and Adolescent Oncofertility. Pediatric and Adolescent Oncofertility
209
229
.
Thomas D. Coates, Susan Carson, John C. Wood & Vasilios Berdoukas. (2016) Management of iron overload in hemoglobinopathies: what is the appropriate target iron level?. Annals of the New York Academy of Sciences 1368:1, pages 95-106.
Crossref
Crossref
Xinhui Wang, Xuexian Fang & Fudi Wang. (2014) Pleiotropic actions of iron balance in diabetes mellitus. Reviews in Endocrine and Metabolic Disorders 16:1, pages 15-23.
Crossref
Crossref
Duantida Songdej, Nongnuch Sirachainan, Pakawan Wongwerawattanakoon, Werasak Sasanakul, Praguywan Kadegasem, Witaya Sungkarat & Ampaiwan Chuansumrit. (2015) Combined Chelation Therapy with Daily Oral Deferiprone and Twice-Weekly Subcutaneous Infusion of Desferrioxamine in Children with β-Thalassemia: 3-Year Experience. Acta Haematologica 133:2, pages 226-236.
Crossref
Crossref
Thomas D. Coates. (2014) Physiology and pathophysiology of iron in hemoglobin-associated diseases. Free Radical Biology and Medicine 72, pages 23-40.
Crossref
Crossref
Vasilios Berdoukas, Anne Nord, Susan Carson, Mammen Puliyel, Thomas Hofstra, John Wood & Thomas D. Coates. (2013) Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age. American Journal of Hematology 88:11.
Crossref
Crossref
Vip Viprakasit, Issarang Nuchprayoon, Ampaiwan Chuansumrit, Kitti Torcharus, Bunchoo Pongtanakul, Jiraporn Laothamatas, Somdet Srichairatanakool, Julaporn Pooliam, Siriwat Supajitkasem, Prapat Suriyaphol, Voravarn S. Tanphaichitr & Soodsarkorn Tuchinda. (2013)
Deferiprone (GPO‐L‐ONE
®
) monotherapy reduces iron overload in transfusion‐dependent thalassemias: 1‐year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO‐L‐ONE; A001) from Thailand
. American Journal of Hematology 88:4, pages 251-260.
Crossref
Crossref
Dimitrios Kountouras, Nikolaos J. Tsagarakis, Evangelia Fatourou, Efthimios Dalagiorgos, Nikolaos Chrysanthos, Helen Berdoussi, Niki Vgontza, Markissia Karagiorga, Athanasios Lagiandreou, Konstantinos Kaligeros, Ersi Voskaridou, Paraskevi Roussou, Evanthia Diamanti‐Kandarakis & John Koskinas. (2013) Liver disease in adult transfusion‐dependent beta‐thalassaemic patients: investigating the role of iron overload and chronic HCV infection. Liver International 33:3, pages 420-427.
Crossref
Crossref
Sezaneh Haghpanah, Shiva Nasirabadi, Fariborz Ghaffarpasand, Rahmatollah Karami, Mojtaba Mahmoodi, Shirin Parand & Mehran Karimi. (2013) Quality of life among Iranian patients with beta-thalassemia major using the SF-36 questionnaire. Sao Paulo Medical Journal 131:3, pages 166-172.
Crossref
Crossref
S.J.S. Flora. 2013. Comprehensive Inorganic Chemistry II. Comprehensive Inorganic Chemistry II
987
1013
.
Janet L. Kwiatkowski. (2011) Real-World Use of Iron Chelators. Hematology 2011:1, pages 451-458.
Crossref
Crossref
Kallistheni Farmaki, Ioanna Tzoumari & Christina Pappa. (2011) Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells, Molecules, and Diseases 47:1, pages 33-40.
Crossref
Crossref